IMMUNOTHERAPY-BASED COMBINATIONS IN THE FIRST-LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA WITH SARCOMATOID FEATURES: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS

被引:0
|
作者
Quhal, Fahad
Mori, Keiichiro
Laukhtina, Ekaterina
Pradere, Benjamin
Mostafaei, Hadi
Rajwa, Pawel
Shariat, Shahrokh F.
Schmidinger, Manuela
机构
来源
JOURNAL OF UROLOGY | 2022年 / 207卷 / 05期
关键词
D O I
暂无
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
MP12-17
引用
收藏
页码:E174 / E174
页数:1
相关论文
共 50 条
  • [31] Is there a preferred first-line therapy for metastatic renal cell carcinoma? A network meta-analysis
    Cattrini, Carlo
    Messina, Carlo
    Airoldi, Chiara
    Buti, Sebastiano
    Roviello, Giandomenico
    Mennitto, Alessia
    Caffo, Orazio
    Gennari, Alessandra
    Bersanelli, Melissa
    [J]. THERAPEUTIC ADVANCES IN UROLOGY, 2021, 13
  • [32] Efficacy and Safety of First-Line Immunotherapy Combinations for Advanced NSCLC: A Systematic Review and Network Meta-Analysis
    Liu, Lihui
    Bai, Hua
    Wang, Chao
    Seery, Samuel
    Wang, Zhijie
    Duan, Jianchun
    Li, Sini
    Xue, Pei
    Wang, Guoqiang
    Sun, Yiting
    Du, Xinyang
    Zhang, Xue
    Ma, Zixiao
    Wang, Jie
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (07) : 1099 - 1117
  • [33] First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis
    Aldin, Angela
    Besiroglu, Burcu
    Adams, Anne
    Monsef, Ina
    Piechotta, Vanessa
    Tomlinson, Eve
    Hornbach, Carolin
    Dressen, Nadine
    Goldkuhle, Marius
    Maisch, Philipp
    Dahm, Philipp
    Heidenreich, Axel
    Skoetz, Nicole
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2023, (05):
  • [34] Comparative Efficacy of First-Line Immune-Based Combination Therapies in Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-Analysis
    Elaidi, Reza
    Phan, Letuan
    Borchiellini, Delphine
    Barthelemy, Philippe
    Ravaud, Alain
    Oudard, Stephane
    Vano, Yann
    [J]. CANCERS, 2020, 12 (06) : 1 - 13
  • [35] First-line systemic treatment for hepatocellular carcinoma: A systematic review and network meta-analysis
    Ciliberto, Domenico
    Carid, Giulio
    Staropoli, Nicoletta
    Romeo, Caterina
    Arillotta, Grazia Maria
    Napoli, Cristina
    Gervasi, Luigia
    Luciano, Francesco
    Riillo, Caterina
    Tassone, Pierfrancesco
    Tagliaferri, Pierosandro
    [J]. HELIYON, 2023, 9 (08)
  • [36] Can we identify a preferred first-line strategy for sarcomatoid renal cell carcinoma? A network meta-analysis
    Buti, Sebastiano
    Bersanelli, Melissa
    Mazzaschi, Giulia
    Cattrini, Carlo
    Brunelli, Matteo
    Di Maio, Massimo
    [J]. IMMUNOTHERAPY, 2022, 14 (02) : 145 - 153
  • [37] Adverse events of systemic immune-based combination therapies in the first-line treatment of patients with metastatic renal cell carcinoma: systematic review and network meta-analysis
    Quhal, Fahad
    Mori, Keiichiro
    Remzi, Mesut
    Fajkovic, Harun
    Shariat, Shahrokh F.
    Schmidinger, Manuela
    [J]. CURRENT OPINION IN UROLOGY, 2021, 31 (04) : 332 - 339
  • [38] Clinical activity of immunotherapy-based combination first-line therapies for metastatic renal cell carcinoma: the right treatment for the right patient
    Borchiellini, Delphine
    Maillet, Denis
    [J]. BULLETIN DU CANCER, 2022, 109 (02) : S4 - S18
  • [39] First-line immunotherapy combinations for recurrent or metastatic nasopharyngeal carcinoma: An updated network meta-analysis and cost-effectiveness analysis
    Han, Jiaqi
    Zeng, Ni
    Tian, Kun
    Liu, Zijian
    She, Longjiang
    Wang, Zhu
    He, Jinlan
    Chen, Nianyong
    [J]. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2023, 45 (09): : 2246 - 2258
  • [40] Systematic review and survival meta-analysis of real world evidence on first-line pazopanib for metastatic renal cell carcinoma
    Climent, Miguel A.
    Munoz-Langa, Jose
    Basterretxea-Badiola, Laura
    Santander-Lobera, Carmen
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2018, 121 : 45 - 50